Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

CHEK2p.I157T Mutation Is Associated with Increased Risk of Adult-Type Ovarian Granulosa Cell Tumors

P. Švajdler, P. Vasovčák, M. Švajdler, M. Šedivcová, V. Urbán, M. Michal, R. Mezencev

. 2022 ; 14 (5) : . [pub] 20220225

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22009921

Pathogenic germline mutations c.1100delC and p.I157T in the CHEK2 gene have been associated with increased risk of breast, colon, kidney, prostate, and thyroid cancers; however, no associations have yet been identified between these two most common European founder mutations of the CHEK2 gene and ovarian cancers of any type. Our review of 78 female heterozygous carriers of these mutations (age > 18 years) found strikingly higher proportion of adult-type granulosa cell tumors of the ovary (AGCTs) among ovarian cancers that developed in these women (~36%) compared to women from the general population (1.3%). Based on this finding, we performed a cross-sectional study that included 93 cases previously diagnosed with granulosa cell tumors, refined and validated their AGCT diagnosis through an IHC study, determined their status for the two CHEK2 mutations, and compared the prevalence of these mutations in the AGCT cases and reference populations. The prevalence ratios for the p.I157T mutation in the AGCT group relative to the global (PR = 26.52; CI95: 12.55-56.03) and European non-Finnish populations (PR = 24.55; CI95: 11.60-51.97) support an association between the CHEK2p.I157T mutation and AGCTs. These rare gynecologic tumors have not been previously associated with known risk factors and genetic predispositions. Furthermore, our results support the importance of the determination of the FOXL2p.C134W somatic mutation for accurate diagnosis of AGCTs and suggest a combination of IHC markers that can serve as a surrogate diagnostic marker to infer the mutational status of this FOXL2 allele.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22009921
003      
CZ-PrNML
005      
20220425131624.0
007      
ta
008      
220420s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14051208 $2 doi
035    __
$a (PubMed)35267514
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Švajdler, Peter $u Cytopathos s. r. o., 831 03 Bratislava, Slovakia $1 https://orcid.org/0000000170200348
245    10
$a CHEK2p.I157T Mutation Is Associated with Increased Risk of Adult-Type Ovarian Granulosa Cell Tumors / $c P. Švajdler, P. Vasovčák, M. Švajdler, M. Šedivcová, V. Urbán, M. Michal, R. Mezencev
520    9_
$a Pathogenic germline mutations c.1100delC and p.I157T in the CHEK2 gene have been associated with increased risk of breast, colon, kidney, prostate, and thyroid cancers; however, no associations have yet been identified between these two most common European founder mutations of the CHEK2 gene and ovarian cancers of any type. Our review of 78 female heterozygous carriers of these mutations (age > 18 years) found strikingly higher proportion of adult-type granulosa cell tumors of the ovary (AGCTs) among ovarian cancers that developed in these women (~36%) compared to women from the general population (1.3%). Based on this finding, we performed a cross-sectional study that included 93 cases previously diagnosed with granulosa cell tumors, refined and validated their AGCT diagnosis through an IHC study, determined their status for the two CHEK2 mutations, and compared the prevalence of these mutations in the AGCT cases and reference populations. The prevalence ratios for the p.I157T mutation in the AGCT group relative to the global (PR = 26.52; CI95: 12.55-56.03) and European non-Finnish populations (PR = 24.55; CI95: 11.60-51.97) support an association between the CHEK2p.I157T mutation and AGCTs. These rare gynecologic tumors have not been previously associated with known risk factors and genetic predispositions. Furthermore, our results support the importance of the determination of the FOXL2p.C134W somatic mutation for accurate diagnosis of AGCTs and suggest a combination of IHC markers that can serve as a surrogate diagnostic marker to infer the mutational status of this FOXL2 allele.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vasovčák, Peter $u Agel Nový Jíčín, a.s., 741 01 Nový Jíčín, Czech Republic
700    1_
$a Švajdler, Marián $u Šikl's Department of Pathology, Charles University in Prague, Faculty of Medicine and Faculty Hospital in Pilsen, 301 00 Pilsen, Czech Republic $u Bioptická Laboratoř s. r. o., 326 00 Pilsen, Czech Republic $1 https://orcid.org/0000000180524741 $7 xx0092880
700    1_
$a Šedivcová, Monika $u Bioptická Laboratoř s. r. o., 326 00 Pilsen, Czech Republic
700    1_
$a Urbán, Veronika $u National Cancer Institute, 833 10 Bratislava, Slovakia
700    1_
$a Michal, Michal $u Šikl's Department of Pathology, Charles University in Prague, Faculty of Medicine and Faculty Hospital in Pilsen, 301 00 Pilsen, Czech Republic $u Bioptická Laboratoř s. r. o., 326 00 Pilsen, Czech Republic
700    1_
$a Mezencev, Roman $u Georgia Institute of Technology, School of Biological Sciences, Atlanta, GA 30332, USA $1 https://orcid.org/0000000343617628 $7 jx20091125006
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 5 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35267514 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220420 $b ABA008
991    __
$a 20220425131622 $b ABA008
999    __
$a ind $b bmc $g 1784437 $s 1161119
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 5 $e 20220225 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20220420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace